Hong‐Hao Zhou

4.5k total citations
107 papers, 3.4k citations indexed

About

Hong‐Hao Zhou is a scholar working on Molecular Biology, Cancer Research and Pharmacology. According to data from OpenAlex, Hong‐Hao Zhou has authored 107 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 36 papers in Cancer Research and 26 papers in Pharmacology. Recurrent topics in Hong‐Hao Zhou's work include Cancer-related molecular mechanisms research (24 papers), Pharmacogenetics and Drug Metabolism (21 papers) and RNA modifications and cancer (20 papers). Hong‐Hao Zhou is often cited by papers focused on Cancer-related molecular mechanisms research (24 papers), Pharmacogenetics and Drug Metabolism (21 papers) and RNA modifications and cancer (20 papers). Hong‐Hao Zhou collaborates with scholars based in China, United States and Malaysia. Hong‐Hao Zhou's co-authors include Zhaoqian Liu, Ji‐Ye Yin, Wei Zhang, Xi Li, Rong Liu, Qiao‐Li Lv, Wei Zhuo, Lei Hu, Zhi‐Rong Tan and Weihua Huang and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Hong‐Hao Zhou

105 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hong‐Hao Zhou China 35 2.1k 1.2k 569 520 341 107 3.4k
Yan Cao China 34 2.1k 1.0× 624 0.5× 435 0.8× 360 0.7× 370 1.1× 172 3.5k
Frank D. Sistare United States 33 1.9k 0.9× 836 0.7× 281 0.5× 327 0.6× 306 0.9× 109 3.9k
Michael Schwarz Germany 34 2.2k 1.1× 852 0.7× 687 1.2× 438 0.8× 129 0.4× 106 3.7k
Hongzhong Li China 32 1.4k 0.7× 535 0.4× 769 1.4× 209 0.4× 445 1.3× 60 2.9k
Ana Ramı́rez de Molina Spain 38 2.3k 1.1× 1.5k 1.2× 631 1.1× 136 0.3× 173 0.5× 141 4.6k
Jun Gu China 39 1.9k 0.9× 634 0.5× 606 1.1× 195 0.4× 215 0.6× 123 3.8k
Qibiao Wu Macao 30 1.2k 0.6× 463 0.4× 453 0.8× 214 0.4× 301 0.9× 147 2.6k
Yingli Wu China 32 2.2k 1.1× 541 0.4× 516 0.9× 170 0.3× 278 0.8× 145 3.2k
Xiaolin Zi United States 39 2.9k 1.4× 663 0.5× 1.3k 2.4× 401 0.8× 223 0.7× 102 4.8k
Qiang Yu China 27 1.3k 0.6× 778 0.6× 302 0.5× 204 0.4× 189 0.6× 36 2.4k

Countries citing papers authored by Hong‐Hao Zhou

Since Specialization
Citations

This map shows the geographic impact of Hong‐Hao Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong‐Hao Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong‐Hao Zhou more than expected).

Fields of papers citing papers by Hong‐Hao Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong‐Hao Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong‐Hao Zhou. The network helps show where Hong‐Hao Zhou may publish in the future.

Co-authorship network of co-authors of Hong‐Hao Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Hong‐Hao Zhou. A scholar is included among the top collaborators of Hong‐Hao Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong‐Hao Zhou. Hong‐Hao Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Yuhui, Yongchao Gao, Man‐Yun Chen, et al.. (2025). Hypoglycemic Effect of Ginsenoside Compound K Mediated by N‐Acetylserotonin Derived From Gut Microbiota. Phytotherapy Research. 39(12). 5491–5505.
2.
Zou, Ting, Junyan Liu, Qun Qin, et al.. (2023). Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines. 11(12). 3133–3133. 4 indexed citations
3.
Zou, Ting, Junyan Liu, Li She, et al.. (2020). The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Pharmacology. 11. 1029–1029. 7 indexed citations
4.
Luo, Chao, Xu Wang, Xiao‐Yuan Mao, et al.. (2020). Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. Psychopharmacology. 237(8). 2257–2277. 10 indexed citations
5.
Fang, Chao, Xiangping Li, Yixin Chen, et al.. (2018). Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. Journal of Thoracic Disease. 10(6). 3329–3340. 13 indexed citations
6.
Li, Qin, et al.. (2018). 12/15 lipoxygenase: A crucial enzyme in diverse types of cell death. Neurochemistry International. 118. 34–41. 44 indexed citations
7.
Liu, Zhaoqian, et al.. (2018). Targeting gap junction in epilepsy: Perspectives and challenges. Biomedicine & Pharmacotherapy. 109. 57–65. 40 indexed citations
8.
Chen, Man‐Yun, Shao Li, Wei Zhang, et al.. (2017). Metabolic analysis of Panax notoginseng saponins with gut microbiota-mediated biotransformation by HPLC-DAD-Q-TOF-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 150. 199–207. 62 indexed citations
9.
10.
Liu, Rong, Ying Zeng, Chengfang Zhou, et al.. (2017). Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Scientific Reports. 7(1). 18–18. 73 indexed citations
11.
Fang, Chao, Yixin Chen, Nayiyuan Wu, et al.. (2017). MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Scientific Reports. 7(1). 40384–40384. 70 indexed citations
12.
Zhang, Xue, et al.. (2017). Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. Journal of Experimental & Clinical Cancer Research. 36(1). 105–105. 83 indexed citations
13.
Wáng, Ying, Xi Li, Wei Zhang, et al.. (2017). Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer. BMC Genomics. 18(1). 901–901. 55 indexed citations
14.
Gong, Weijing, Ji‐Ye Yin, Xiangping Li, et al.. (2016). Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumor Biology. 37(6). 8349–8358. 150 indexed citations
15.
Jia, Feifei, Jamie K. Teer, Todd C. Knepper, et al.. (2016). Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. Molecular Diagnosis & Therapy. 21(2). 179–185. 25 indexed citations
16.
Li, Zhenyu, Xiaolan Deng, Weihua Huang, et al.. (2014). Lignans from the bark of Eucommia ulmoides inhibited Ang II-stimulated extracellular matrix biosynthesis in mesangial cells. Chinese Medicine. 9(1). 8–8. 23 indexed citations
17.
Zhou, Boting, Ji‐Ye Yin, Guoliang Li, et al.. (2012). Effects of SCN1A and GABA Receptor Genetic Polymorphisms on Carbamazepine Tolerability and Efficacy in Chinese Patients with Partial Seizures: 2‐Year Longitudinal Clinical Follow‐Up. CNS Neuroscience & Therapeutics. 18(7). 566–572. 41 indexed citations
18.
Yu, Bangning, Chen‐Hui Luo, Dan Wang, et al.. (2004). CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clinica Chimica Acta. 348(1-2). 57–61. 50 indexed citations
19.
Huang, Ping, Bing Zhu, Liansheng Wang, et al.. (2003). Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. European Journal of Clinical Pharmacology. 59(5-6). 471–476. 10 indexed citations
20.
Wen-xing, Peng, LI Huan-de, & Hong‐Hao Zhou. (2003). Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. European Journal of Clinical Pharmacology. 59(3). 237–241. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026